Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 63 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 18F-Fluciclovine Clear all
Not listed Phase 3 Interventional

18F-Fluciclovine PET Imaging for Detecting High Grade Glioma Recurrence After Radiochemotherapy

NCT05479136
View directory record Official record
Conditions
Grade III or Grade IV Glioma
Interventions
PET imaging with 18F fluciclovine
Drug
Lead sponsor
Nicole Hill
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 20, 2026, 5:38 AM EDT
Recruiting Phase 2 Interventional

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

NCT06064097
View directory record Official record
Conditions
Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Chest Radiography, Cisplatin, Computed Tomography, Echocardiography Test, Electronic Health Record Review, Fluciclovine F18, Gemcitabine, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, X-Ray Imaging
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
76
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 20, 2026, 5:38 AM EDT
Completed Phase 2Phase 3 Interventional Results available

FACBC Outcomes for Post Prostatectomy

NCT01666808
View directory record Official record
Conditions
Prostate Cancer
Interventions
FACBC, Radiation therapy
Drug · Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years to 95 Years · Male only
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Oct 20, 2026, 5:38 AM EDT
Completed Phase 1 Interventional

[18F]Fluciclovine in Post-treatment Glioblastoma ( Axumin )

NCT03990285
View directory record Official record
Conditions
Glioma Glioblastoma Multiforme
Interventions
Axumin, Intravenous Solution
Drug
Lead sponsor
Ali Nabavizadeh
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 22, 2021 · Synced Oct 20, 2026, 5:38 AM EDT
Completed Not applicable Interventional

PET/MRI Study of Men With Highly Suspicious MRI Lesions That Showed no Clinically Significant Prostate Cancer Following MRI Fusion Targeted Biopsy

NCT03635866
View directory record Official record
Conditions
Prostate Cancer
Interventions
Fluciclovine PET/MRI
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Oct 20, 2026, 5:38 AM EDT
Terminated Phase 2 Interventional Results available

GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer

NCT01176513
View directory record Official record
Conditions
Prostate Cancer
Interventions
GE-148 (18F)
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 20, 2026, 5:38 AM EDT
Recruiting Phase 4 Interventional

Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

NCT07569926
View directory record Official record
Conditions
Prostate Cancer
Interventions
fluciclovine (18F)
Drug
Lead sponsor
Blue Earth Diagnostics
Industry
Eligibility
18 Years and older · Male only
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
6
States / cities
San Diego, California • Atlanta, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 20, 2026, 5:38 AM EDT
Completed No phase listed Observational

Role of Axumin PET Scan in Germ Cell Tumor

NCT03426865
View directory record Official record
Conditions
Testis Cancer, Germ Cell Tumor, Testicular Cancer, Germ Cell Tumor of Testis, Germ Cell Tumor, Testicular, Childhood, Testicular Neoplasms, Testicular Germ Cell Tumor, Testicular Yolk Sac Tumor, Testicular Choriocarcinoma, Testicular Diseases, Germ Cell Cancer Metastatic, Germ Cell Neoplasm of Retroperitoneum, Germ Cell Cancer, Nos
Interventions
Axumin PET scan
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 20, 2026, 5:38 AM EDT
Not listed Phase 2 Interventional

Radiotherapy Planning Using Fluciclovine PET in Patients With Newly Diagnosed Glioblastoma

NCT04840069
View directory record Official record
Conditions
Newly Diagnosed Glioblastoma
Interventions
Fluciclovine PET guided Radiotherapy
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 13, 2023 · Synced Oct 20, 2026, 5:38 AM EDT
Completed Phase 2 Interventional Results available

18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies

NCT04158245
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
18F-fluciclovine PET Scan
Drug
Lead sponsor
Tulane University
Other
Eligibility
18 Years to 18 Years · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 20, 2026, 5:38 AM EDT
Terminated Phase 4 Interventional Results available

Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer.

NCT03423082
View directory record Official record
Conditions
Cervical Cancer, Uterine Cancer
Interventions
18F fluciclovine, 18F fluciclovine PET
Drug · Device
Lead sponsor
Nghi Nguyen
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 20, 2026, 5:38 AM EDT
Recruiting Phase 1 Interventional

Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT

NCT06062745
View directory record Official record
Conditions
Advanced Prostate Cancer, Metastatic Prostate Cancer, Metastatic Prostate Neuroendocrine Carcinoma
Interventions
18F-fluciclovine, PET/CT
Drug · Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 20, 2026, 5:38 AM EDT
Completed Phase 1 Interventional Results available

Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer

NCT04750473
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Lobular Carcinoma, Metastatic Breast Lobular Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Computed Tomography, Fluciclovine F18, Gallium Ga 68 Gozetotide, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Oct 20, 2026, 5:38 AM EDT
Completed Phase 2 Interventional Results available

FACBC for Recurrent Prostate Cancer

NCT01808222
View directory record Official record
Conditions
Recurrent Prostate Cancer
Interventions
FACBC
Drug
Lead sponsor
David M. Schuster, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 20, 2026, 5:38 AM EDT
Completed Phase 1 Interventional

Amino Acid Tracer (FACBC) Positron Emission Tomography for Lung Nodule

NCT01502670
View directory record Official record
Conditions
Lung Cancer
Interventions
18F-FACBC Radiotracer
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 20, 2026, 5:38 AM EDT
Terminated Phase 2 Interventional Results available

FACBC Positron Emission Tomography/Computed Tomography(PET/CT) Used in the Diagnosis of Primary Prostate Cancer

NCT00917865
View directory record Official record
Conditions
Prostate Cancers
Interventions
anti [18F]FACBC
Drug
Lead sponsor
David M. Schuster, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Oct 20, 2026, 5:38 AM EDT
Recruiting Phase 2 Interventional

Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis

NCT05554302
View directory record Official record
Conditions
Brain Metastases, Brain Cancer
Interventions
18F-Fluciclovine
Drug
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Oct 20, 2026, 5:38 AM EDT
Recruiting Phase 2 Interventional

Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial

NCT06319027
View directory record Official record
Conditions
Glioblastoma, IDH-Wildtype
Interventions
Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Fluciclovine F18, Gadolinium-Chelate, Magnetic Resonance Spectroscopy, Positron Emission Tomography
Procedure · Other · Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 20, 2026, 5:38 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

[18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors

NCT03276676
View directory record Official record
Conditions
Brain Tumor
Interventions
[18F]FLT, [18F]Fluciclovine
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 20, 2026, 5:38 AM EDT
Completed Phase 3 Interventional Results available

Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases

NCT04410133
View directory record Official record
Conditions
Brain Metastases
Interventions
18F fluciclovine
Drug
Lead sponsor
Blue Earth Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 20, 2026, 5:38 AM EDT
Active, not recruiting Phase 2 Interventional

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

NCT05053152
View directory record Official record
Conditions
Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Ductal Adenocarcinoma, Prostate Intraductal Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Fluciclovine F18, Magnetic Resonance Imaging, Placebo Administration, Positron Emission Tomography, PSMA PET Scan, Relugolix, Stereotactic Body Radiation Therapy
Procedure · Other · Drug + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2034
U.S. locations
242
States / cities
Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 192 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 20, 2026, 5:38 AM EDT
Recruiting Phase 4 Interventional

18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer

NCT06706921
View directory record Official record
Conditions
Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Metastatic Prostate Cancer, Male Urogenital Diseases, Prostatic Diseases, Urogenital Diseases, Male, Genital Diseases, Male, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Genital Neoplasms, Male
Interventions
18F-Fluciclovine PET/CT Scan
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 20, 2026, 5:38 AM EDT
Completed No phase listed Observational

Prostate Cancer Patients With Biochemical Recurrence

NCT03527199
View directory record Official record
Conditions
Patients With Prostate Cancer
Interventions
Pelvic CT or MRI + MDP bone scan + or - 18F-NaF PET/CT(SOC)
Diagnostic Test
Lead sponsor
Medhat Osman
Federal
Eligibility
18 Years to 89 Years · Male only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Oct 20, 2026, 5:38 AM EDT
Recruiting Early Phase 1 Interventional

Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG

NCT05555550
View directory record Official record
Conditions
Glioma, Low-grade Glioma, Low Grade Glioma of Brain, Glioma, Malignant, Glioma Intracranial
Interventions
18F-Fluciclovine
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Year to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 20, 2026, 5:38 AM EDT